Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer

Berretta, Roberto; Sozzi, Gabriella; Volpi, Lavinia; Ceni, Valentina; Melpignano, Mauro; Giordano, Giovanna; Marchesi, Federico; Monica, Michela; Serio, Maurizio Di; Riccò, Matteo; Ceccaroni, Marcello

doi:10.1007/s00404-018-4675-y

Cited by 13 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FIGO specifically restricts the definition of Stage IIIA1 disease to retroperitoneal lymph nodes (pelvic and para-aortic) but does not indicate how tumor spread to intraperitoneal nodes (such as those in the mesentery or omentum) should be interpreted, although it would be very unusual to have isolated nodal metastases at these sites (5). According to FIGO (personal communication), this should be regarded as intra-abdominal disease, that is, Stage IIIC (78,79). At present there are also limited data to justify the subdivision of Stage IIIA1 according to the size of the nodal metastases (5).…”

Section: Lymph Node Statusmentioning

confidence: 99%

Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR)

Gilks

Selinger

Davidson

et al. 2022

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

The move toward consistent and comprehensive surgical pathology reports for cancer resection specimens has been a key development in supporting evidence-based patient management and consistent cancer staging. The International Collaboration on Cancer Reporting (ICCR) previously developed a data set for reporting of the ovarian, fallopian tube and primary peritoneal carcinomas which was published in 2015. In this paper, we provide an update on this data set, as a second edition, that reflects changes in the 2020 World Health Organization (WHO) Classification of Female Genital Tumours as well as some other minor modifications. The data set has been developed by a panel of internationally recognized expert pathologists and a clinician and consists of "core" and "noncore" elements to be included in surgical pathology reports, with detailed commentary to guide users, including references. This data set replaces the widely used first edition, and will facilitate consistent and accurate case reporting, data collection for quality assurance and research, and allow for comparison of epidemiological and pathologic parameters between different populations.

show abstract

Section: Lymph Node Statusmentioning

confidence: 99%

Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR)

Gilks

Selinger

Davidson

et al. 2022

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

“…The open approach allows better macroscopical exploration and removal of the gross tumor without mass rupture. Laparotomy is believed to be superior at identifying occult metastasis through increased exposure and palpation that could otherwise be missed by MIS [95]. In clinical practice, MIS has been considered with encouraging results for early-stage ovarian carcinomas in high volume centres with experienced surgeons [43][44][45].…”

Section: Ovarian Cancermentioning

confidence: 99%

Minimally invasive surgery in gynecological cancers: update and systematic review

Scarpelli¹,

Armano²,

Monfardini³

et al. 2022

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Introduction:In the last decades, the introduction of laparoscopy and, more recently, of robotic surgery, offered new options for surgical treatment also in gynecological malignancies, as an alternative to open surgery. When considering the best surgical treatment option for gynecological malignancies, evidence about safety, feasibility, and oncological outcomes must be taken into account, to offer the best treatment to the patient. The present review aims to provide an updated scenario over the available evidence in the use of minimally invasive surgery (MIS) in gynecological malignancies. Material and methods: An electronic search was performed using the following keywords: 'minimally invasive surgery' and 'gynecology', 'minimally invasive surgery' and 'endometrial cancer', 'minimally invasive surgery' and 'ovarian cancer', 'minimally invasive surgery' and 'cervical cancer'. The agreement about potential relevance was reached by consensus of the researchers and according to PRISMA statement guidelines. Systematic reviews, meta-analyses, clinical trials, and original articles were included in the present review. Results: Fifty-eight studies were considered eligible for the study, 23 studies regarding MIS in endometrial cancer (EC), 19 studies on MIS in ovarian cancer (OC), and 16 studies regarding MIS in cervical cancer (CC). The total of patients enrolled was 180,057, 131,430 in the EC group, 23,774 in the OC groups, and 24,853 in the CC group. Conclusions: According to the available evidence and current clinical practice, MIS is undoubtedly the gold standard for early-stage EC treatment and may represent an acceptable option even in high-risk EC patients. Concerning OC, MIS is a safe and useful tool for staging purposes in advanced-stage disease, and a treatment option only in high volume centres with expert oncologic surgeons. On the contrary, MIS should be abandoned in the context of CC, exception made for well-selected patients, who received adequate counselling about current evidence.

show abstract

“…Recently, LODDS staging was hypothesized to be a better predictor of survival in many cancers compared with LNR and PLN staging ( 18 , 21 ). Previously, LODDS was used to analyze the prognostic role of mesenteric lymph nodes (MLNs) involvements in AOC ( 22 ). However, the prognostic value of LODDS in AOC remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery

et al. 2022

View full text Add to dashboard Cite

PurposeTo analyze the relationship between neoadjuvant chemotherapy (NACT) and log odds of positive lymph nodes (LODDS), as well as their prognostic role in advanced ovarian cancer (AOC) patients with optimal cytoreductive surgery.Patients and MethodsFrom the SEER database during 2010-2016, we identified 1,012 AOC patients with optimal cytoreductive surgery. Univariable and multivariable logistic regression was performed to identify the relationship between NACT and LODDS. Overall survival (OS) and cancer-specific survival (CSS) were assessed using the Kaplan-Meier method and log-rank test. Univariable and multivariable Cox regression was conducted to determine the independent prognostic factors for OS and CSS.ResultsFactors associated with significantly higher NACT odds included older (≥60 years old), married, tumor size ≥ 15 cm, FIGO IV, and LODDS ≤ 0.1. Multivariable Cox regression model confirmed older (≥60 years old), unmarried, separated, divorced, widowed, mucinous histology type, tumor size ≥ 15 cm, and LODDS > 0.1 were correlated with increased risks of OS and CSS. NACT was not an independent prognostic factor for OS and CSS. In the subgroup analyses, LODDS was an independent prognostic factor for OS and CSS in patients with < 75 years old, married, unmarried, FIGO III, and tumor size < 15 cm.ConclusionNACT did not show any survival benefit in AOC patients with optimal cytoreductive surgery, but it may be beneficial in reducing LODDS. Meanwhile, clinicians can use grade of LODDS to predict the prognosis of AOC patients with optimal cytoreductive surgery.

show abstract

Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer

Cited by 13 publications

References 26 publications

Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR)

Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR)

Minimally invasive surgery in gynecological cancers: update and systematic review

Relationship Between Neoadjuvant Chemotherapy and Log Odds of Positive Lymph Nodes and Their Prognostic Role in Advanced Ovarian Cancer Patients With Optimal Cytoreductive Surgery

Contact Info

Product

Resources

About